Key Takeaways
- Cosentyx is the first anti-IL-17 biologic approved for polymyalgia rheumatica, for patients who respond inadequately to steroids or cannot taper them.
- In REPLENISH (n=381), sustained remission at Week 52 was 40.5% on the 150 mg dose versus 20.5% on placebo.
- Patients on Cosentyx also accumulated about 20% less steroid exposure over the year.
Why Would a Second Biologic Matter for a Disease Steroids Already Treat?
Because for polymyalgia rheumatica, the treatment has long been nearly as punishing as the disease. PMR strikes adults over 50 with acute pain and stiffness in the shoulders, neck and hips — "remarkably ordinary things" become hard, as one patient advocate put it: getting out of bed, getting dressed, lifting your arms. About 966,000 people in the United States live with it.
The standard treatment is corticosteroids, and they work — until they don't. Up to 40% of patients relapse in the first year, and long-term steroid use raises the risk of osteoporosis, cardiovascular disease and diabetes. Many patients face a choice between the disease and the drug.
The FDA has now approved Cosentyx (secukinumab) for adults with PMR who have had an inadequate response to corticosteroids or who cannot tolerate a steroid taper. It is the first and only anti-IL-17 biologic approved for the disease — the second biologic overall — and Novartis's 11th U.S. indication for the drug.
What the Trial Showed
The approval rests on REPLENISH, a phase 3 trial published in the New England Journal of Medicine, which randomized 381 patients with relapsed PMR across 27 countries to secukinumab or placebo, each combined with a 24-week steroid taper.
The headline result: 40.5% of patients on the approved 150 mg dose achieved sustained remission at Week 52 — remission held from Week 12 through Week 52 — versus 20.5% on placebo. Patients on Cosentyx also accumulated roughly 20% less steroid over the year (an adjusted average of 1,683 mg versus 2,093 mg).
"The prospect of months or years of additional steroids is disheartening," said Prof. John Stone of Harvard Medical School and Massachusetts General Hospital, the trial's global principal investigator. "Secukinumab doubled the likelihood of sustained remission while helping patients taper off steroids, which should be the goal of PMR treatment."
The honesty beat matters here. The drug did not help most patients reach sustained remission — six in ten on the 150 mg dose did not meet that strict endpoint. Serious adverse events were somewhat more common on Cosentyx than placebo (15.9% versus 14.2%), and the trial record includes one fatal case of cryptococcal meningitis in a Cosentyx-treated patient. The results come from patients whose disease had already relapsed, so they do not automatically describe newly diagnosed patients.
Health note: Cosentyx is a prescription biologic given by injection under the skin — 150 mg weekly for the first five doses, then every four weeks, alongside a tapering steroid course. Anyone with PMR should discuss benefits, infection risks and steroid tapering with their own rheumatologist; do not stop steroids suddenly.
The Twikup Take
PMR care has been stuck for decades between a disease that hurts and a cure that harms. A drug that doubles sustained remission while cutting steroid exposure by a fifth does not end that dilemma — but for patients who relapse or cannot taper, it is the first genuinely new option aimed at the disease's own pathway.
Image: Illustrative image.
